CD8A and neoplasm: Tumeh et al. studied a cohort of samples from metastatic melanoma patients and found that those with a higher CD8+ T cell density at the invasive margin before treatment were more likely to respond to pembrolizumab therapy and could also correlate to a radiographic reduction of tumor size.